
"Express Mail" mailing label number EL618954548US
Date of Deposit: November 9, 2001
I hereby certify that this paper/fee is being deposited with the US Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to The Assistant Commissioner for Patents, Washington, DC 20231

Larry L. Huston
32,994
Attorney
Reg. No.



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

Signature

:

JAFFER, ET AL.

:

Serial No.:

Secretary Secretary in the

Group Art Unit:

Filed: November 9, 2001

Examiner:

Confirmation No.:

For: Die For Extruding Flowable Materials and Having Static Mixer Therein

#### INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

# 1. [X] 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [] 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

## 3. [] 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

## THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

- (a) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.
- (b) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.
- (C) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 does <u>not</u> indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.
- 4. [] 37 C.F.R. §1.97 (b)(4) (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

- 5. [] <u>Information to be Considered with CPA Filing</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).
- 6. [] 37 C.F.R. \$1.97(c) with fee payment (use after 1<sup>st</sup> Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

## ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

SAMMATAN.
[] (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior
application Case No. 11.5. Part of A. 11. 11. 2. 11
application Case No, U.S. Patent Application Serial No, filed Applicants claim priority to
said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this
Statement, pursuant to 37 C.F.R. §1.98(d).
OR
(2) Copies of the cited documents are enclosed.
OR
ri .
, were submitted and
considered in parent application U.S. Patent Application Serial No, filed,
Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document
No.'s are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies
of document No.'s are enclosed. It is respectfully requested that the cited documents be
carefully considered by the Examiner and made of record in this case.
(4) Pursuant to 37 C.F.R. \$1.98(c), a concise explanation of the relevance of each six 1.5
313 6(9), a concise explanation of the relevance of each cited reference
that is not in the English language is provided.
[X] (5) Applicants also respectfully request the Examiner to consider and make of record the
copending applications listed on the attached page.
1 stand approvations instead on the attached page.
Additional information to the second
Additional information is attached.
Respectfully submitted,
By
Attorney
<i></i>

Registration No. 32,994 Customer Number: 27752

(513) 634-9358 NN 9, 201) Company of a

### **COPENDING APPLICATIONS**

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) <u>must</u> be sent with the IDS (see 37 CFR 1.98(a)(2)(iii)

Atty. Docket No.	Serial Number	<u>Inventor(s)</u>	Filing Date
8774		Shaffiq Amin Jaffer, et a.	November 9, 2001

[ones that are pending at time of this filing; others that have issued get cited on the PTO/SB08.]